Audible Premium Plus. $0.99/mo for the first 3 months + $20 Audible credits. 12 days only. Get this deal. Cancel anytime.

Our take on the REACH losmapimod clinical trial results
Sep 19 2024
Length: 1 hr and 58 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to Cart failed.

Please try again later

Add to Wish List failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Please try again

Unfollow podcast failed

Please try again

Our take on the REACH losmapimod clinical trial results

Listen for free

View show details

Summary
"I always tell the truth, even when I lie." Today we are joined by our CRISPR Goddess and cover the Fulcrum Therapeutics REACH phase 3 clinical trial data release and discuss our journey with Fulcrum from the beginning. While very disappointing from several aspects, in the end a lot of benefit truly has been gained for the FSHD field and we are grateful for Fulcrum's contributions to help others going forward. And there are many others coming along, this is the beginning and not the end for FSHD therapeutics.

Show more Show less

Show more Show less

What listeners say about Our take on the REACH losmapimod clinical trial results

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon